source
- Eli Lilly to file FDA application for obesity drug retatrutide after Phase 3 trial resultsEli Lilly announced that two additional Phase 3 trials of its experimental obesity medicine retatrutide met their primary goals, and the company plans to submit an FDA application for the drug next…
- Eli Lilly to seek approval next year for retatrutide after strong Phase 3 obesity resultsEli Lilly announced that its experimental obesity drug retatrutide will be submitted to regulators for approval early next year. The decision follows recent Phase 3 trial data that showed the drug…